Clesrovimab
Product Specifications
UNSPSC Description
Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection[1][2].
Target Antigen
RSV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/clesrovimab.html
Purity
99.62
Solubility
10 mM in DMSO
Smiles
[Clesrovimab]
References & Citations
[1]Qiu X, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53.|[2]Odumade OA, et al. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection. Clin Infect Dis. 2022 Aug 15;75(Supplement_1):S130-S135.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99804/Clesrovimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99804/Clesrovimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2429913-18-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items